UBAP2L has been reported to be highly expressed in multiple cancers, and knockdown of UBAP2L could suppress malignant behaviors in cancer cells, including breast cancer, hepatocellular carcinoma, and prostate cancer [13–15]. Here, UBAP2L is linked to prostate cancer.